11例经分析确认的甲氧麻黄酮使用案例:多重药物使用者中的表现
本文报告11例经尿液毒理学分析确认使用甲氧麻黄酮的病例,来自305例因使用多种精神活性物质就诊的患者。激越是最常见表现(10/11),部分达攻击程度,6例需镇静和/或约束;3例出现妄想和幻觉(常伴偏执,主题突出超自然/恶魔),均无精神病史;7/11心率>100次/分。中位住院时间20小时(范围2-77,IQR 4-33)。仅2例甲氧麻黄酮可能单独解释临床表现,2例高浓度合并大量其他兴奋剂,7例其他兴奋剂更可能解释表现。患者通常24小时内完全恢复,除非需要镇静。
要点
- 在305例多重药物使用就诊者中,经尿液UPLC-MS/MS和精确质量TOF筛查确认11例甲氧麻黄酮使用。
- 激越为最常见表现(10/11),部分达攻击程度,6例需镇静和/或物理约束。
- 3例出现妄想和幻觉(常伴偏执,主题突出超自然/恶魔),均无精神病史。
- 7/11心率>100次/分;中位住院时间20小时(范围2-77,IQR 4-33)。
- 仅2例甲氧麻黄酮可能单独解释表现,2例高浓度合并大量其他兴奋剂,7例其他兴奋剂更可能解释表现;患者通常24小时内完全恢复,除非需要镇静。
适用人群与场景
- 因使用多种精神活性物质(包括甲氧麻黄酮)就诊于本医院的患者,每例均经分析确认。
红旗征与不能漏的情况
- 激越达攻击程度,6例需镇静和/或物理约束。
- 妄想和幻觉(常伴偏执,主题突出超自然/恶魔),3例出现,均无精神病史。
- 窦性心动过速,7/11心率>100次/分。
研究设计与关键结果
- 观察性病例系列:305例筛查中11例尿液样本检出甲氧麻黄酮。
- 激越最常见(10/11),6例需镇静和/或物理约束;3例出现妄想和幻觉(常伴偏执,主题突出超自然/恶魔),均无精神病史。
- 7/11心率>100次/分;中位住院时间20小时(范围2-77,IQR 4-33)。
- 仅2例甲氧麻黄酮可能单独解释临床表现;2例高浓度合并大量其他兴奋剂;7例其他兴奋剂更可能解释表现。
- 患者通常24小时内完全恢复,除非需要镇静。
证据类型、等级与局限
- 证据类型:观察性病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对多重药物使用后出现激越、攻击行为、妄想幻觉(超自然/恶魔主题)及窦性心动过速的患者,应考虑甲氧麻黄酮等兴奋剂可能,并送尿液毒理学分析确认。
- 甲氧麻黄酮可能单独解释表现(2例),但常与其他兴奋剂共同作用(2例高浓度合并大量其他兴奋剂,7例其他兴奋剂更可能解释表现),需综合 analytical 数据判断。
- 患者通常24小时内完全恢复,除非需要镇静;需镇静者恢复可能延迟。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Mexedrone, 3-methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-one, is the alpha-methoxy-derivative of mephedrone (4-methyl-N-methyl cathinone). Mexedrone inhibits the re-uptake of serotonin and dopamine in a dose-dependent manner and has affinity for serotonin and dopamine membrane transporters and receptors (5-HT2 and D2 receptors), producing sympathomimetic effects similar to amfetamines. To date there are no published clinical reports on mexedrone use that are analytically confirmed.
OBJECTIVE: To characterise the features of mexedrone use in patients who presented to our hospital after using a variety of psychoactive substances including mexedrone, with analytical confirmation in each case.
METHODS: This is an observational case series. Urine toxicological screening using ultra-performance liquid chromatography with tandem mass spectrometry and exact mass time of flight was employed in all patients.
RESULTS: A total of 305 cases were screened and mexedrone was identified in 11 urine samples. Agitation was the most common presenting feature in 10 of 11 patients. This was marked to the extent of aggression in some cases, with six patients requiring sedation and/or physical restraint. Delusions and hallucinations, often with paranoia, were observed in three cases with a prominent supernatural/demonic theme. None of these individuals had a history of psychosis. Seven of 11 patients were tachycardic >100 bpm. The median length of stay was 20 hours (range 2-77; IQR 4-33). Mexedrone alone is only likely to have been responsible for these clinical features in 2 cases; in two others mexedrone was found in high concentration along with substantial amounts of other stimulants. In 7 other cases other stimulants detected more likely explained the features. However, comprehensive analytical data enabled us to identify the full complement of agents contributing to the clinical presentation.
CONCLUSIONS: Agitation was the predominant clinical feature in this case series and was often accompanied by a sinus tachycardia; mexedrone was primarily responsible in 2 patients but contributed substantially in two others. Patients typically recovered fully within 24 hours, unless they required sedation.
参考来源
- Roberts L, Ford L, Patel N, et al. 11 analytically confirmed cases of mexedrone use among polydrug users. Clin Toxicol (Phila). 2017. PMID: 28075189. doi:10.1080/15563650.2016.1271424
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。